SCHEMBL1472541

SCHEMBL1472541

Clc1ccc(-c2cn3cc(Br)ccc3n2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.82
RAB9A P51151 9/20 0.75
NPC1 O15118 8/20 0.75
SMN1; SMN2 Q16637 3/20 0.68
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
LMNA P02545 2/20 0.68
NFKB1 P19838 1/20 0.68
NFKB2 Q00653 1/20 0.68
RELA Q04206 1/20 0.68
APP P05067 6/20 0.66
ALDH1A3 P47895 2/20 0.65
PAX8 Q06710 2/20 0.64
KDM4E B2RXH2 4/20 0.55
POLB P06746 2/20 0.55
MITF O75030 1/20 0.53
KDM5A P29375 1/20 0.53
KDM5C P41229 1/20 0.53
MAPT P10636 1/20 0.53
CASP3 P42574 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7605200 0.90 NPC1 (0.77) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
Bromide SCHEMBL1691853 0.89 ALDH1A1 (0.80) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
Bromide SCHEMBL1691457 0.88 NPC1 (0.75) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL1691409 0.86 RAB9A (1.00) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL1473062 0.85 NPC1 (0.81) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL1727295 0.83 APP (0.66) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL14076016 0.83 APP (0.66) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL1691526 0.83 APP (0.66) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL5776511 0.83 APP (0.67) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL5302309 0.83 ALDH1A3 (0.75) ALDH1A1RAB9ANPC1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160120863-A1 SLC2A TRANSPORTER INHIBITORS IOMET PHARMA LTD. (GB) 2016-05-05 US disclosed
US-20160120863-A1 SLC2A TRANSPORTER INHIBITORS IOMET PHARMA LTD. (GB) 2016-05-05 US disclosed
US-20160120863-A1 SLC2A TRANSPORTER INHIBITORS IOMET PHARMA LTD. (GB) 2016-05-05 US disclosed
EP-3004088-A1 SLC2A TRANSPORTER INHIBITORS Iomet Pharma Ltd. (GB) 2016-04-13 EP disclosed
WO-2014187922-A1 SLC2A TRANSPORTER INHIBITORS IOMET PHARMA LTD. (GB) 2014-11-27 WO disclosed
WO-2014187922-A1 SLC2A TRANSPORTER INHIBITORS IOMET PHARMA LTD. (GB) 2014-11-27 WO disclosed
EP-2262769-B1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-05 EP disclosed
US-8507520-B2 Polysubstituted 2-aryl-6-phenylimidazo[1,2-A]pyridine derivatives, and preparation and therapeutic use thereof SANOFI (FR) 2013-08-13 US disclosed
EP-2262803-B1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-10-17 EP disclosed
US-8148370-B2 Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-04-03 US disclosed
US-7915284-B2 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-29 US disclosed
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed
EP-2262769-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-12-22 EP disclosed
EP-2069342-B1 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-05-12 EP disclosed
WO-2009144394-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO disclosed
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF NCOR1, NR4A2, NR4A3 ALDH1A1 1788/4885RAB9A 4133/4885NPC1 781/4885
US-20160120863-A1 SLC2A TRANSPORTER INHIBITORS SLCO1A2, SLCO2B1, SLCO2A1 ALDH1A1 629/4885RAB9A 1287/4885NPC1 137/4885
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF JAK2, ABL1, REN ALDH1A1 148/4885RAB9A 1509/4885NPC1 996/4885
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN ALDH1A1 193/4885RAB9A 1452/4885NPC1 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.